PropertyValue
?:abstract
  • The World Health Organization (WHO) has declared coronavirus disease 2019 (COVID-19) is the first pandemic caused by coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, there is no effective anti-SARS-CoV-2 drug approved worldwide for treatment of patients with COVID-19. Therapeutic options in response to the COVID-19 outbreak are urgently needed. To facilitate the better and faster development of therapeutic COVID-19 drugs, we present an overview of the global promising therapeutic drugs, including repurposing existing antiviral agents, network-based pharmacology research, antibody development and traditional Chinese medicine. Among all these drugs, we focus on the most promising drugs (such as favipiravir, tocilizumab, SARS-CoV-2 convalescent plasma, hydroxychloroquine, Lianhua Qingwen, interferon beta-1a, remdesivir, etc.) that have or will enter the final stage of human testing—phase III–IV clinical trials.
?:creator
?:doi
  • 10.1007/s12250-020-00297-0
?:doi
?:journal
  • Virol_Sin
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/9e136a2ce9ae46caa7bae686ce9f3a81dcf189a4.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7524871.xml.json
?:pmcid
?:pmid
?:pmid
  • 32997322.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine
?:type
?:year
  • 2020-09-30

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/essgkkv1>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/essgkkv1>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all